Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
28 Marzo 2024 - 1:00PM
Business Wire
– Presentation highlights beneficial effects of
chronic EDG-7500 treatment in preventing diastolic dysfunction in
an animal model of non-obstructive hypertrophic cardiomyopathy
(HCM) –
Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle
disease biopharmaceutical company, today announced that the Company
will present data on EDG-7500 at the American College of
Cardiology's Annual Scientific Session (ACC.24). EDG-7500 is a
first-in-class oral, selective, cardiac sarcomere modulator,
specifically designed to slow early contraction velocity and
address impaired cardiac relaxation associated with HCM and other
diseases of diastolic dysfunction. The conference will take place
in Atlanta, GA at the Georgia World Congress Center from April 6-8,
2024.
“EDG-7500 is a novel investigational therapy for the treatment
of HCM with a differentiated mechanism of action,” said Kevin Koch,
Ph.D., President and Chief Executive Officer, Edgewise
Therapeutics. “Importantly, in our preclinical studies, EDG-7500
has shown potent gradient reduction, normalization of hyperdynamic
contractility, and significant improvements in ventricular filling.
At ACC, data supporting beneficial effects of chronic EDG-7500
treatment in preventing diastolic dysfunction in an animal model of
non-obstructive HCM will be presented and discussed. Despite recent
therapeutic advances in obstructive HCM, patients with symptomatic
non-obstructive disease have limited options.”
Edgewise Presentation at ACC.24:
Session: From the bench to the bedside:
Advances in heart failure & cardiomyopathies
Poster Presentation: 1087-05 - Chronic Treatment with the
Novel Sarcomere Modulator EDG-7500 Improves Left Ventricular
Distensibility and Cardiac Output Recruitment Under Stress in a
Mini-pig Genetic Model of Non-Obstructed Hypertrophic
Cardiomyopathy
Presenter: Marc Evanchik, Vice President Discovery and
Translational Pharmacology, Edgewise Therapeutics
Date: Sunday, April 7, 2024, 3:15 – 3:25 pm ET
The scientific poster will be available on the Edgewise website
after it is presented.
About EDG-7500 for HCM
EDG-7500 is a first-in-class oral, selective, cardiac sarcomere
modulator, specifically designed to slow early contraction velocity
and address impaired cardiac relaxation associated with HCM and
other diseases of diastolic dysfunction. Preclinical data in models
of both obstructed and non-obstructed HCM suggest the ability to
drive a broadly effective clinical response at a low risk of
decreasing left ventricular ejection fraction below normal at all
doses tested. Due to EDG-7500’s self-limiting mechanism on systolic
contraction, the Company plans to investigate fixed-dose regimens
of EDG-7500, thus potentially eliminating the echo-mediated dose
titration and intense follow-up requirements of current therapy.
The Company is advancing a randomized, placebo-controlled, single
and multiple ascending dose Phase 1 trial evaluating safety,
tolerability, PK and pharmacodynamics in healthy adults. To learn
more about this trial (NCT06011317), go to clinicaltrials.gov.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease
biopharmaceutical company developing novel therapeutics for
muscular dystrophies and serious cardiac conditions. The Company’s
deep expertise in muscle physiology is driving a new generation of
first-in-class therapeutics. EDG-5506 is an orally administered
skeletal myosin inhibitor in clinical trials in patients with
Becker, Duchenne, and Limb-Girdle muscular dystrophies as well as
McArdle Disease. EDG-7500, currently in a Phase 1 trial, is a novel
cardiac sarcomere modulator for the treatment of HCM and other
disorders of cardiac diastolic dysfunction. The entire team at
Edgewise is dedicated to our mission: changing the lives of
patients and families affected by serious muscle diseases. To learn
more, go to: www.edgewisetx.com or follow us on LinkedIn, X
(formerly Twitter), Facebook, Instagram and Threads.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240328046868/en/
Edgewise Contacts Investors: Michael Carruthers,
Chief Financial Officer ir@edgewisetx.com Media: Maureen
Franco, VP Corporate Communications media@edgewisetx.com
Grafico Azioni Edgewise Therapeutics (NASDAQ:EWTX)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Edgewise Therapeutics (NASDAQ:EWTX)
Storico
Da Dic 2023 a Dic 2024
